**Abstract**

Inflammation has been raised as a candidate of unifying pathogenesis and a target of disease modifying strategy for Alzheimer's disease(AD). A cytokine, endothelial-monocyte-activating polypeptide-2 (EMAP-2) which amplifies actions of tumor necrosis factor alpha (TNF-alpha), might be an important target, since it is involved in microglial activation and neuronal death. We hypothesize that EMAP-2 is associated with the Alzheimer's disease, and anti-EMAP-2 antibody could have therapeutic effects on cognitive impairment in amyloid beta-induced AD model animals.

We investigated the association between the EMAP-2 gene, the -9299A/G polymorphism and cognitive impairment in 641 subjects aged from 60 to 80. In addition, we compared EMAP-2 concentration in peripheral blood among people with AD (n = 30), mild cognitive impairment (n = 29), or normal cognition (n = 27). Finally, we examined the effects of anti-EMAP-2 antibody following injecting it to AD model rats on cognitive function using water maze and passive avoidance tests and on a level of cell death in the brain tissue using TUNEL assay.

We found a significant association between the -9299A/G polymorphism (GG vs AG/AA) of EMAP-2 gene and cognitive impairment. GG homozygote compared to A-allele carriers was related to lower mini-mental status examination score (p = 0.001). In addition, EMAP-2 level was significantly higher in the peripheral blood of people with AD than in that of healthy control group (p = 0.05). In the AD model rats, injection of EMAP-2 antibody improved short-term memory (p \< 0.01) and fear memory (p \< 0.05), and lowered the levels of neuronal cell death in the brain tissue (p \< 0.05)

Our results suggested a possible involvement of EMAP-2 in AD pathogenesis, as well as the potential of humanized anti-EMAP-2 antibody as a novel option for AD treatment.
